Professor, Internal Medicine, Washington University School of Medicine
Hematology
Dr. Katherine P. Ponder, MD
|
|
Give Review
Doctor Katherine P. Ponder, MD practices Hematology. She researched medicine at Washington University School of Medicine in St. Louis. Katherine P. Ponder is a published doctor as well. She has 77 publications published. The latest was: Therapeutic levels of human protein C in rats after retroviral vector-mediated hepatic gene therapy.
Publications
- A review of gene therapy in canine and feline models of lysosomal storage disorders.
- The effect of Tlr4 and/or C3 deficiency and of neonatal gene therapy on skeletal disease in mucopolysaccharidosis VII mice.
- Effects of Neonatal Enzyme Replacement Therapy and Simvastatin Treatment on Cervical Spine Disease in Mucopolysaccharidosis I Dogs.
- Pathogenesis of mitral valve disease in mucopolysaccharidosis VII dogs.
- The effect of neonatal gene therapy with a gamma retroviral vector on cardiac valve disease in mucopolysaccharidosis VII dogs after a decade.
- Retroviral-vector-mediated gene therapy to mucopolysaccharidosis I mice improves sensorimotor impairments and other behavioral deficits.
- The effect of neonatal gene therapy on skeletal manifestations in mucopolysaccharidosis VII dogs after a decade.
- Postnatal progression of bone disease in the cervical spines of mucopolysaccharidosis I dogs.
- Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases.
- FIXing Factor VIII inhibitors.
- Merry Christmas for Patients with Hemophilia B.
- Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation.
- Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management.
- Status of therapeutic gene transfer to treat cardiovascular disease in dogs and cats.
- Hemophilia gene therapy: a Holy Grail found.
- Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I.
- Altered lumbar spine structure, biochemistry, and biomechanical properties in a canine model of mucopolysaccharidosis type VII.
- Upregulation of elastase activity in aorta in mucopolysaccharidosis I and VII dogs may be due to increased cytokine expression.
- A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in mice.
- Mechanism of shortened bones in mucopolysaccharidosis VII.
- Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy.
- Neonatal intravenous injection of a gammaretroviral vector has a low incidence of tumor induction in mice.
- Immune response hinders therapy for lysosomal storage diseases.
- Upregulation of elastase proteins results in aortic dilatation in mucopolysaccharidosis I mice.
- Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy.
- Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation.
- Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice.
- Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice.
- Cutting edge: treatment of complement regulatory protein deficiency by retroviral in vivo gene therapy.
- Gene therapy for hemophilia.
- Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig.
- Expression in blood cells may contribute to biochemical and pathological improvements after neonatal intravenous gene therapy for mucopolysaccharidosis VII in dogs.
- Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy.
- In vivo transduction of hematopoietic stem cells after neonatal intravenous injection of an amphotropic retroviral vector in mice.
- Neonatal retroviral vector-mediated hepatic gene therapy reduces bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogs.
- Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B.
- Should gene therapy be used for newborns with hemophilia?
- Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy.
- Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs.
- Transduction of hepatocytes after neonatal delivery of a Moloney murine leukemia virus based retroviral vector results in long-term expression of beta-glucuronidase in...
- Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model.
- C/EBPbeta contributes to hepatocyte growth factor-induced replication of rodent hepatocytes.
- Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice.
- Clinical characterization of cardiovascular abnormalities associated with feline mucopolysaccharidosis I and VI.
- Unresolved issues in diagnosis and management of inherited bleeding disorders in the perinatal period: a White Paper of the Perinatal Task Force of the Medical and Sci...
- Lipopolysaccharide results in a marked decrease in hepatocyte nuclear factor 4 alpha in rat liver.
- Lipopolysaccharide potentiates the effect of hepatocyte growth factor upon replication in lung, thyroid, spleen, and colon in rats in vivo.
- Delivery of a retroviral vector expressing human beta-glucuronidase to the liver and spleen decreases lysosomal storage in mucopolysaccharidosis VII mice.
- Lovastatin decreases mortality and improves liver functions in fulminant hepatic failure from 90% partial hepatectomy in rats.
- Systemic gene therapy for cardiovascular disease.
- Lipopolysaccharide potentiates the effect of hepatocyte growth factor on hepatocyte replication in rats by augmenting AP-1 activity.
- Intramuscular injection of an adenoviral vector expressing hepatocyte growth factor facilitates hepatic transduction with a retroviral vector in mice.
- Embolization of portal vein branches induces hepatocyte replication in swine: a potential step in hepatic gene therapy.
- Therapeutic levels of human protein C in rats after retroviral vector-mediated hepatic gene therapy.
- Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy.
- Portal branch occlusion safely facilitates in vivo retroviral vector transduction of rat liver.
- Alterations in enzymatic functions in hepatocytes and hepatocellular carcinomas from Ras-transduced livers resemble the effects of insulin.
- Liver-directed gene therapy: a retroviral vector with a complete LTR and the ApoE enhancer-alpha 1-antitrypsin promoter dramatically increases expression of human alph...
- Retroviral vector sequences may interact with some internal promoters and influence expression.
- Analysis of liver development, regeneration, and carcinogenesis by genetic marking studies.
- In vivo hepatocyte transduction with retrovirus during in-flow occlusion.
- Liver-directed gene therapy: quantitative evaluation of promoter elements by using in vivo retroviral transduction.
- Liver-directed gene therapy: evaluation of liver specific promoter elements.
- Optimization of liver-directed retroviral gene delivery.
- Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes.
- Ras-transduced diethylnitrosamine-treated hepatocytes develop into cancers of mixed phenotype in vivo.
- Experiments in transgenic mice show that hepatocytes are the source for postnatal liver growth and do not stream.
- Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation.
- Evaluation of relative promoter strength in primary hepatocytes using optimized lipofection.
- Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes.
- Human gene therapy: present and future.
- Walk a mile in the moccasins of people with haemophilia.
- Immunology of neonatal gene transfer.
- Gene therapy for mucopolysaccharidosis.
- High expression reduces an antibody response after neonatal gene therapy with B domain-deleted human factor VIII in mice.
- Gene therapy ameliorates cardiovascular disease in dogs with mucopolysaccharidosis VII.
Schools
Washington Center School of Medicine
Dallas Co Hp Parkland Mem
University Tx Sw Med Center Affil Hsps
Doctors Specialties
- Internal Medicine
- Hematology
Accepted Insurances
Education
-
Yale New Haven Children's Center -
Washington University School of Medicine in St. Louis
Helpful Reviews
Similar Doctors
|
|
Dr. Jeffrey P. Ward, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. C S. Molden, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pilaipun Williams, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ananth K. Arjunan, MD |
|
Dr. Joseph T. Hilgeman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Atif Shafqat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy J. Ley, MD |
|
|
Dr. Douglas M. Tollefsen, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|